search
Back to results

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Primary Purpose

Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor

Status
Recruiting
Phase
Phase 2
Locations
Taiwan
Study Type
Interventional
Intervention
CVM-1118
Sponsored by
TaiRx, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neuroendocrine Tumors focused on measuring Oncology, Neuroendocrine Tumors, NET, Vasculogenic mimicry

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients eligible for inclusion in this study must meet ALL of the following criteria:

  1. [Tumor eligibility] Histologically or cytologically confirmed advanced (unresectable and/or metastatic) neuroendocrine tumors that are well-differentiated, low or intermediate grade (WHO Grade 1 or 2) of pancreatic or gastrointestinal, or low/ intermediate grade of lung origin, that are refractory to standard of care therapy, or for whom no standard of care therapy is available.
  2. Patients must have measurable or evaluable disease as per RECIST criteria v1.1. Target lesions that have been previously irradiated will not be considered measurable (lesion) unless increase in size is observed following completion of radiation therapy.
  3. Patients must have documented progressive disease within 6 months prior enrollment after prior therapy.
  4. Patients who are on therapy with a somatostatin analog are eligible but progressive disease must be demonstrated subsequent to establishment for at least 3 months of a stable dose.
  5. Male or female, 20 years of age or older.
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
  7. Resolution of all acute toxic effects of prior therapy or surgical procedures to Grade 1 (except alopecia).
  8. Adequate organ function as defined by the following criteria:

    • Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≦ 3 x upper limit of normal (ULN), or AST and ALT ≦ 5 x ULN if liver function abnormalities are due to underlying malignancy
    • Total serum bilirubin ≦ 1.5 x ULN (except for patients with documented Gilbert's syndrome)
    • Absolute neutrophil count (ANC) ≧ 1500/µL
    • Platelets ≧ 90,000/µL
    • Hemoglobin ≧ 9.0 g/dL
    • Serum creatinine ≦ 2.0 x ULN or creatinine clearance of ≧ 50 mL/min
  9. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
  10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria:

Patients eligible for this study must not meet ANY of the following criteria:

  1. Poorly differentiated neuroendocrine carcinoma, or high grade neuroendocrine tumor.
  2. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
  3. Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of starting study treatment.
  4. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.
  5. Current treatment on another clinical trial.
  6. Patients who are using other investigational agents or who had received investigational drugs within 4 weeks prior to study enrollment.
  7. Brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks.
  8. Any of the following within the 12 months prior to starting study treatment:

    myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack; within 6 months prior to starting study treatment for pulmonary embolus. However, upon agreement between the investigator and sponsor, the 6-month post-event-free period for a patient with a pulmonary embolus can be waived if due to advanced cancer. Appropriate treatment with anticoagulants is permitted.

  9. Hypertension that cannot be controlled by medications (> 160/100 mmHg despite optimal medical therapy).
  10. Current treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
  11. Known history of human immunodeficiency virus (HIV) seropositivity and/or is receiving anti-retroviral therapy.
  12. Hepatitis B virus (HBV) or hepatitis C virus (HCV) with evidence of chronic active disease or receiving/requiring antiviral therapy.
  13. History of receiving organ transplantation or immune disorders that require continuous immunosuppressant agent therapy.
  14. Pregnancy or breastfeeding. Female patients must be surgically sterile or be postmenopausal or must agree to the use of effective contraception during the period of therapy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the Investigator or a designated associate.
  15. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that would impart, in the judgment of the investigator and/or Sponsor, excess risk associated with study participation or study drug administration, which would make the patient inappropriate for entry into this study.

Sites / Locations

  • Chang Gung Memorial Hospital, KaoHsiungRecruiting
  • Kaohsiung Medical University HospitalRecruiting
  • China Medical University HospitalRecruiting
  • Taichung Veterans General HospitalRecruiting
  • National Cheng Kung University HospitalRecruiting
  • Taipei Veterans General HospitalRecruiting
  • Chang Gung Memorial Hospital, LinKouRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

CVM-1118

Arm Description

CVM-1118 200mg or 300mg Bis In Die (BID) daily/ Cycle (28 days per cycle)

Outcomes

Primary Outcome Measures

Time-to progression-free survival (PFS)
Measure the Time-to PFS or death to any cause. The tumor assessment will be performed every 12 weeks until documented disease progression, death, or date of follow-up.

Secondary Outcome Measures

Objective response rate (ORR)
ORR is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR), based on the investigator's assessment as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1.
Disease control rate (DCR)
DCR is defined as the proportion of patients with a best overall response of CR, PR, or Stable Disease (SD), based on the investigator's assessment per RECIST criteria v1.1.
Duration of overall response (DoR)
DoR is measured only for the responder subset: patients with confirmed CR or PR based on the investigator's assessment. It is the elapsed time between the date of first documented response and the following date of event defined as the first documented disease progression or death due to underlying cancer, per RECIST criteria v1.1.
Time-to progression (TTP)
TTP is defined as the duration of time from initiation of study medication to first documentation of tumor progression.
Time-to overall survival (OS)
OS is defined as the duration of time from initiation of study medication to death due to any cause.
Number of participants with treatment-related adverse events (AEs) as assessed by CTCAE v4.03
Assessment of adverse events will based on the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE].
Number of Participants With Abnormal baseline and out-of range Hematology Count by CTCAE v4.03
Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.
Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range urinalysis test by CTCAE v4.03
Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.
Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range coagulation test by CTCAE v4.03
Normal range of PT/PTT will be provided. Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided.
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ body temperature by CTCAE v4.03
Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ blood pressure by CTCAE v4.03
Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ heart rate by CTCAE v4.03
Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ respiratory rate by CTCAE v4.03
Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.
Abnormalities in electrocardiography (ECG)
a 12-lead (with a 10-second rhythm strip) tracing, with a capacity to calculate the standard intervals automatically, will be used.
Maximum Plasma Concentration [Cmax] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing
PK parameters will be calculated for CVM-1118 and its metabolite CVM-1125 during this study.
Area Under the Curve [AUC] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing
PK parameters will be calculated for CVM-1118 and its metabolite CVM-1125 during this study.
Pharmacodynamics analysis for the relationship of Cmax and PFS
The correlations of PK parameter, Cmax and key efficacy endpoint will be evaluated in this study.
Pharmacodynamics analysis for the relationship of AUC and PFS
The correlations of PK parameter, AUC and key efficacy endpoint will be evaluated in this study.
Pharmacodynamics analysis for the relationship of AUC and AE
The correlations of PK parameter, AUC and key safety endpoint will be evaluated in this study.
Pharmacodynamics analysis for the relationship of Cmax and AE
The correlations of PK parameter, Cmax and key safety endpoint will be evaluated in this study.

Full Information

First Posted
June 7, 2018
Last Updated
August 24, 2021
Sponsor
TaiRx, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03600233
Brief Title
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Official Title
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients With Advanced Neuroendocrine Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Recruiting
Study Start Date
December 15, 2018 (Actual)
Primary Completion Date
November 2022 (Anticipated)
Study Completion Date
November 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
TaiRx, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 for patients with advanced neuroendocrine tumors.
Detailed Description
Neuroendocrine tumors (NETs) are a group of uncommon heterogeneous malignancies originating from neuroendocrine cells localized throughout the body. Approximately 50% of patients with NETs would have metastatic cancer, where 65% of patients with metastatic cancer would result in mortality within 5 years of diagnosis. The current treatments of NETs do not follow single discipline and the effective agents are largely still under clinical investigations. Apparent formation of vasculogenic mimicry (VM) has been reported in at least two types of NETs. Moreover, VM has been found as part of multiple microvascular alterations in mouse models of pancreatic neuroendocrine tumors. Wih the high potential of inhibiting VM formation, CVM-1118 is considered to have therapeutic potentials in treating NET tumors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm, Neuroendocrine Carcinoma
Keywords
Oncology, Neuroendocrine Tumors, NET, Vasculogenic mimicry

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CVM-1118
Arm Type
Experimental
Arm Description
CVM-1118 200mg or 300mg Bis In Die (BID) daily/ Cycle (28 days per cycle)
Intervention Type
Drug
Intervention Name(s)
CVM-1118
Other Intervention Name(s)
TRX-818
Intervention Description
Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose). Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met.
Primary Outcome Measure Information:
Title
Time-to progression-free survival (PFS)
Description
Measure the Time-to PFS or death to any cause. The tumor assessment will be performed every 12 weeks until documented disease progression, death, or date of follow-up.
Time Frame
12 months after the last patient enrolled
Secondary Outcome Measure Information:
Title
Objective response rate (ORR)
Description
ORR is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR), based on the investigator's assessment as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1.
Time Frame
up to 12 months after the last patient enrolled
Title
Disease control rate (DCR)
Description
DCR is defined as the proportion of patients with a best overall response of CR, PR, or Stable Disease (SD), based on the investigator's assessment per RECIST criteria v1.1.
Time Frame
up to 12 months after the last patient enrolled
Title
Duration of overall response (DoR)
Description
DoR is measured only for the responder subset: patients with confirmed CR or PR based on the investigator's assessment. It is the elapsed time between the date of first documented response and the following date of event defined as the first documented disease progression or death due to underlying cancer, per RECIST criteria v1.1.
Time Frame
up to 12 months after the last patient enrolled
Title
Time-to progression (TTP)
Description
TTP is defined as the duration of time from initiation of study medication to first documentation of tumor progression.
Time Frame
up to 12 months after the last patient enrolled
Title
Time-to overall survival (OS)
Description
OS is defined as the duration of time from initiation of study medication to death due to any cause.
Time Frame
up to 12 months after the last patient enrolled
Title
Number of participants with treatment-related adverse events (AEs) as assessed by CTCAE v4.03
Description
Assessment of adverse events will based on the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE].
Time Frame
During the course of the trial or within 28 days following termination from the trial
Title
Number of Participants With Abnormal baseline and out-of range Hematology Count by CTCAE v4.03
Description
Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.
Time Frame
From baseline of screening up to end of treatment or withdraw, an average of 12 months
Title
Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range urinalysis test by CTCAE v4.03
Description
Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.
Time Frame
From baseline of screening up to end of treatment or withdraw, an average of 12 months
Title
Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range coagulation test by CTCAE v4.03
Description
Normal range of PT/PTT will be provided. Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided.
Time Frame
From baseline of screening up to end of treatment or withdraw, an average of 12 months
Title
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ body temperature by CTCAE v4.03
Description
Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.
Time Frame
From baseline of screening up to end of treatment or withdraw, an average of 12 months
Title
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ blood pressure by CTCAE v4.03
Description
Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.
Time Frame
From baseline of screening up to end of treatment or withdraw, an average of 12 months
Title
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ heart rate by CTCAE v4.03
Description
Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.
Time Frame
From baseline of screening up to end of treatment or withdraw, an average of 12 months
Title
Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ respiratory rate by CTCAE v4.03
Description
Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.
Time Frame
From baseline of screening up to end of treatment or withdraw, an average of 12 months
Title
Abnormalities in electrocardiography (ECG)
Description
a 12-lead (with a 10-second rhythm strip) tracing, with a capacity to calculate the standard intervals automatically, will be used.
Time Frame
From baseline of screening up to end of treatment or withdraw, an average of 12 months
Title
Maximum Plasma Concentration [Cmax] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing
Description
PK parameters will be calculated for CVM-1118 and its metabolite CVM-1125 during this study.
Time Frame
Cycle 1 and Cycle 2 (each cycle is 28 days)
Title
Area Under the Curve [AUC] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing
Description
PK parameters will be calculated for CVM-1118 and its metabolite CVM-1125 during this study.
Time Frame
Cycle 1 and Cycle 2 (each cycle is 28 days)
Title
Pharmacodynamics analysis for the relationship of Cmax and PFS
Description
The correlations of PK parameter, Cmax and key efficacy endpoint will be evaluated in this study.
Time Frame
Cycle 1 and Cycle 2 (each cycle is 28 days)
Title
Pharmacodynamics analysis for the relationship of AUC and PFS
Description
The correlations of PK parameter, AUC and key efficacy endpoint will be evaluated in this study.
Time Frame
Cycle 1 and Cycle 2 (each cycle is 28 days)
Title
Pharmacodynamics analysis for the relationship of AUC and AE
Description
The correlations of PK parameter, AUC and key safety endpoint will be evaluated in this study.
Time Frame
Cycle 1 and Cycle 2 (each cycle is 28 days)
Title
Pharmacodynamics analysis for the relationship of Cmax and AE
Description
The correlations of PK parameter, Cmax and key safety endpoint will be evaluated in this study.
Time Frame
Cycle 1 and Cycle 2 (each cycle is 28 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients eligible for inclusion in this study must meet ALL of the following criteria: [Tumor eligibility] Histologically or cytologically confirmed advanced (unresectable and/or metastatic) neuroendocrine tumors that are well-differentiated, low or intermediate grade (WHO Grade 1 or 2) of pancreatic or gastrointestinal, or low/ intermediate grade of lung origin, that are refractory to standard of care therapy, or for whom no standard of care therapy is available. Patients must have measurable or evaluable disease as per RECIST criteria v1.1. Target lesions that have been previously irradiated will not be considered measurable (lesion) unless increase in size is observed following completion of radiation therapy. Patients must have documented progressive disease within 6 months prior enrollment after prior therapy. Patients who are on therapy with a somatostatin analog are eligible but progressive disease must be demonstrated subsequent to establishment for at least 3 months of a stable dose. Male or female, 20 years of age or older. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. Resolution of all acute toxic effects of prior therapy or surgical procedures to Grade 1 (except alopecia). Adequate organ function as defined by the following criteria: Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≦ 3 x upper limit of normal (ULN), or AST and ALT ≦ 5 x ULN if liver function abnormalities are due to underlying malignancy Total serum bilirubin ≦ 1.5 x ULN (except for patients with documented Gilbert's syndrome) Absolute neutrophil count (ANC) ≧ 1500/µL Platelets ≧ 90,000/µL Hemoglobin ≧ 9.0 g/dL Serum creatinine ≦ 2.0 x ULN or creatinine clearance of ≧ 50 mL/min Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. Exclusion Criteria: Patients eligible for this study must not meet ANY of the following criteria: Poorly differentiated neuroendocrine carcinoma, or high grade neuroendocrine tumor. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy. Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of starting study treatment. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue. Current treatment on another clinical trial. Patients who are using other investigational agents or who had received investigational drugs within 4 weeks prior to study enrollment. Brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks. Any of the following within the 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack; within 6 months prior to starting study treatment for pulmonary embolus. However, upon agreement between the investigator and sponsor, the 6-month post-event-free period for a patient with a pulmonary embolus can be waived if due to advanced cancer. Appropriate treatment with anticoagulants is permitted. Hypertension that cannot be controlled by medications (> 160/100 mmHg despite optimal medical therapy). Current treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed). Known history of human immunodeficiency virus (HIV) seropositivity and/or is receiving anti-retroviral therapy. Hepatitis B virus (HBV) or hepatitis C virus (HCV) with evidence of chronic active disease or receiving/requiring antiviral therapy. History of receiving organ transplantation or immune disorders that require continuous immunosuppressant agent therapy. Pregnancy or breastfeeding. Female patients must be surgically sterile or be postmenopausal or must agree to the use of effective contraception during the period of therapy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the Investigator or a designated associate. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that would impart, in the judgment of the investigator and/or Sponsor, excess risk associated with study participation or study drug administration, which would make the patient inappropriate for entry into this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shu-Yuan Lin
Phone
886-2-2789-1060
Ext
307
Email
shuyuan@effpha.com
First Name & Middle Initial & Last Name or Official Title & Degree
Karis Chiang
Phone
886-2-2789-1060
Ext
306
Email
karis.chiang@effpha.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wu-Chou Su
Organizational Affiliation
National Cheng Kung University Hospital,Taiwan
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chang Gung Memorial Hospital, KaoHsiung
City
Kaohsiung
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yen-Yang Chen, MD
Facility Name
Kaohsiung Medical University Hospital
City
Kaohsiung
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
I-Chen Wu, MD
Facility Name
China Medical University Hospital
City
Taichung
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li-Yuan Bai, MD
Facility Name
Taichung Veterans General Hospital
City
Taichung
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yu-Hsuan Shih, MD
Facility Name
National Cheng Kung University Hospital
City
Tainan
ZIP/Postal Code
704
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wu-Chou Su, MD
Facility Name
Taipei Veterans General Hospital
City
Taipei
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ming-Huang Chen, MD
Facility Name
Chang Gung Memorial Hospital, LinKou
City
Taoyuan City
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jen-Shi Chen, MD

12. IPD Sharing Statement

Learn more about this trial

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

We'll reach out to this number within 24 hrs